| Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. ARYB Lee, SY Wong, LYA Chai, SC Lee, MX Lee, MD Muthiah, SH Tay, ... BMJ (Clinical research ed.) 376, e068632-e068632, 2022 | 383 | 2022 |
| Biomarkers for homologous recombination deficiency in cancer MM Hoppe, R Sundar, DSP Tan, AD Jeyasekharan JNCI: Journal of the National Cancer Institute 110 (7), 704-713, 2018 | 286 | 2018 |
| Nivolumab in NSCLC: latest evidence and clinical potential R Sundar, BC Cho, JR Brahmer, RA Soo Therapeutic advances in medical oncology 7 (2), 85-96, 2015 | 247 | 2015 |
| Combining DNA damaging therapeutics with immunotherapy: more haste, less speed JS Brown, R Sundar, J Lopez British journal of cancer 118 (3), 312-324, 2018 | 231 | 2018 |
| Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer V Kumar, K Ramnarayanan, R Sundar, N Padmanabhan, S Srivastava, ... Cancer discovery 12 (3), 670-691, 2022 | 192 | 2022 |
| Immunotherapy in the treatment of non-small cell lung cancer R Sundar, R Soong, BC Cho, JR Brahmer, RA Soo Lung Cancer 85 (2), 101-109, 2014 | 148 | 2014 |
| Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients … A Molassiotis, HL Cheng, V Lopez, JSK Au, A Chan, A Bandla, KT Leung, ... BMC cancer 19 (1), 1-19, 2019 | 145 | 2019 |
| Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics DC Collins, R Sundar, JSJ Lim, TA Yap Trends in pharmacological sciences 38 (1), 25-40, 2017 | 111 | 2017 |
| Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma JJ Zhao, DWT Yap, YH Chan, BKJ Tan, CB Teo, NL Syn, EC Smyth, ... Journal of Clinical Oncology 40 (4), 392-402, 2022 | 100 | 2022 |
| Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐and platinum‐based chemotherapy A Molassiotis, HL Cheng, KT Leung, YC Li, KH Wong, JSK Au, R Sundar, ... Brain and behavior 9 (6), e01312, 2019 | 98 | 2019 |
| Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression CAW Ng, AA Jiang, EMS Toh, CH Ng, ZH Ong, S Peng, HY Tham, ... International journal of colorectal disease 35 (8), 1501-1512, 2020 | 83 | 2020 |
| Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review CK Cheong, KRY Nistala, CH Ng, N Syn, HSY Chang, R Sundar, ... Journal of Gastrointestinal Oncology 11 (5), 847, 2020 | 62 | 2020 |
| First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid TumorsPhase I Study of TAS-116, a Novel Oral HSP90 Inhibitor A Shimomura, N Yamamoto, S Kondo, Y Fujiwara, S Suzuki, N Yanagitani, ... Molecular Cancer Therapeutics 18 (3), 531-540, 2019 | 61 | 2019 |
| Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer SO Dolly, DC Collins, R Sundar, S Popat, TA Yap Drugs 77 (8), 813-827, 2017 | 58 | 2017 |
| A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore. N Ngoi, J Lim, S Ow, WY Jen, M Lee, W Teo, J Ho, R Sundar, ML Tung, ... Annals of Oncology, 2020 | 56 | 2020 |
| Targeting ATR in cancer medicine R Sundar, J Brown, AI Russo, TA Yap Current problems in cancer 41 (4), 302-315, 2017 | 56 | 2017 |
| Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy J Yeong, HYJ Lum, CB Teo, BKJ Tan, YH Chan, RYK Tay, JRE Choo, ... Gastric Cancer 25 (4), 741-750, 2022 | 55 | 2022 |
| PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal MetastasesPIPAC-Oxaliplatin Phase I Study for … G Kim, HL Tan, R Sundar, B Lieske, CE Chee, J Ho, A Shabbir, MV Babak, ... Clinical Cancer Research 27 (7), 1875-1881, 2021 | 54 | 2021 |
| Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or … L Carter European Journal of Cancer, 2016 | 51 | 2016 |
| Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer R Sundar, KK Huang, A Qamra, KM Kim, ST Kim, WK Kang, ALK Tan, ... Annals of Oncology 30 (3), 424-430, 2019 | 49 | 2019 |
Aishwarya BandlaNational University of SingaporeVerified email at nus.edu.sg
